We claim:

1. A formulation comprising

i) fenofibric acid, or a physiologically acceptable salt or derivative thereof, and optionally other active substances;

ii) a binder component comprising at least one enteric binder; and optionally

iii) other physiologically acceptable excipients.

2. The formulation as claimed in claim 1, wherein the physiologically acceptable derivative of fenofibric acid is fenofibrate.

3. The formulation as claimed in claim 1, wherein fenofibric acid, the physiologically acceptable salt or derivative thereof is in the form of a molecular dispersion.

4. The formulation as claimed in claim 1, wherein the enteric binder is an enteric polymer.

5. The formulation as claimed in claim 4, wherein the enteric polymer is selected from hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, carboxymethylethylcellulose, cellulose acetate phthalate, cellulose acetate trimellitate and carboxymethylcellulose sodium.

6. The formulation as claimed in claim 4, wherein the enteric polymer is selected from copolymers based on (meth)acrylic acid and at least one alkyl (meth)acrylic acid ester.

7. The formulation as claimed in claim 6, wherein the alkyl (meth)acrylic acid ester is methyl methacrylate.

8. The formulation as claimed in claim 6, wherein the copolymer has a ratio of free carboxyl groups to esterified carboxyl groups of around 2:1 to 1:3.

9. The formulation of claim 8, wherein the ratio is around 1:1.

10. The formulation as claimed in claim 1, wherein the formulation comprises

i) 5 to 60% by weight, preferably 7 to 40% by weight and in particular 10 to 30% by weight of active substance component;

ii) 20 to 95% by weight, preferably 30 to 90% by weight and in particular 40 to 85% by weight, of binder component;

iii) 0 to 75% by weight, preferably 1 to 60% by weight and in particular 5 to 40% by weight, of other physiologically acceptable excipients.

11. The formulation as claimed in claim 1, wherein the enteric binder preferably constitutes 5 to 95 % by weight, more preferably 10 to 70 % by weight and, in particular, 30 to 60 % by weight of the binder component (ii).

12. The formulation as claimed in claim 1, wherein the content of active substance component (i) relative to binder component (ii) is from 1 to 50% by weight, preferably 10 to 40% by weight and in particular 20 to 30% by weight.

13. The formulation as claimed in claim 1, comprising

i) fenofibric acid or fenofibrate;

ii) at least one binder selected from enteric polymers; and optionally

iii) other physiologically acceptable excipients, especially a flow regulator, e.g. highly disperse silica gel.

14. The formulation as claimed in any one of the preceding claims, obtainable by melt extrusion of a mixture comprising fenofibric acid, a physiologically acceptable salt or derivative thereof, binder and optionally other active substances and/or other physiologically acceptable excipients.

15. A method for oral administration of fenofibric acid, a physiologically acceptable salt or derivative thereof, comprising administering a formulation as claimed in any one of claims 1 to 14, optionally with the addition of other excipients, as dosage form.

16. Dosage form comprising a formulation as claimed in any one of claims 1 to 14.